, Bharathi Avula 3 and Ikhlas A Khan 3, 4 Recently, we published a Letter to the Editor (''Letter'') in Annals of Nutrition and Metabolism entitled ''The color of rice and the Chinese paradox''. 1 Red Yeast Rice (RYR), the subject of the Letter, is touted as ''nature's source'' of the statins. RYR has both been consumed as a traditional food staple (''traditional RYR'') by the eastern Chinese provinces over many centuries 2 and sold commercially as a health supplement over the last two decades (''RYR supplement''). Current popular belief is that traditional RYR and RYR supplement are one in the same; however, as we will describe, this is a misconception. In our Letter, we presented the following hypothesis: could the lower incidence of cardiovascular disease (CVD) observed in Chinese provinces that consume traditional RYR compared with those provinces that do not be related to the lifetime of consumption of traditional RYR with its presumed statin content? After the publication of our Letter, we decided to reexamine the statin content of traditional RYR. Our findings, in conjunction with the following historical background, may impact our recommendation on the usage of RYR supplements to our patients.
The discovery of the statins heralded a new era in the management of both primary and secondary prevention of CVD. 3 A pioneering Japanese researcher, Akira Endo, began searching for an inhibitor of HMG-CoA reductase from the fermentation of literally thousands of fungal broths. 4 The HMG-CoA reductase inhibitor he discovered was isolated from a fermentation catalyzed by Monascus purpureus, the same fungus utilized in the preparation of traditional RYR. The statin he isolated was Monacolin K (also known as lovastatin).
The M. pupureus story begins in antiquity. Traditional RYR has been a Chinese food staple consumed for centuries in the Eastern Chinese Provinces; it is a food product that results from the fermentation of white rice and the fungus M. purpureus. The red color is imparted by various pigments that result from the fermentation process. RYR supplement capsules, presumed to contain desiccated traditional RYR product, are ubiquitous in health food stores, pharmacies and supermarkets. The active ingredients in RYR supplements are ascribed to the statin contents (principle statin is lovastatin), which are also products of the fermentation process. One of the initial articles on RYR describes the efficacy of RYR supplement in lowering serum lipids in a clinical setting in China. The authors clearly state ''the M. Purpureus preparation . . . is prepared by a traditional rice fermentation method''. 5 However, the fermentation conditions were modified to enhance statin production. Within several years after the emergence of the first pharmaceutical statin on the market, the RYR supplement industry emerged. A ''natural'' supplement derived from a traditional food with health benefits related to the natural lovastatin content became the core of the marketing strategy. This strategy was derailed in the late 1990s by a United States Food and Drug Administration (FDA) investigation which had ascertained that the majority of the traditional RYR they tested contained no statins. 6 At the time, lovastatin was a pharmaceutical on the market under FDA regulation. The FDA reasoned that the absence of statins in traditional RYR compared with statin content in RYR supplement implied that the supplement industry was marketing a regulated drug as an unregulated ''natural'' product. This finding is not widely known and has not been widely published in the medical literature. The FDA subsequently mandated that no RYR supplement sold in the United States may legally contain more than trace amounts of statins.
In the course of our investigation we discovered that the industrial production of supplemental RYR and some pharmaceutical statins (lovastatin) are similar, if not identical. Adjustments of various parameters such as pH, oxygen tension and temperature, as well as specific strain of Monascus may be manipulated to increase the production of statins. [7] [8] [9] In contrast, the industrial production of supplemental RYR is dissimilar from the recipe for traditional RYR. In fact, RYR supplement with higher statin content is often not red. Additionally, lovastatin producing strains of Monascus are poor producers of red pigments. 9 The conditions which optimize statin production minimize red pigment production. One of the key methodologies utilized to maximize statin content is maintenance of fermentation temperature at 25 C. The traditional RYR fermentation generates heat that leads to higher fermentation temperatures and a red color. Another byproduct of this process is the production of the renal toxic metabolite, citrinin, which has been found in some RYR supplements. 10 Traditional RYR was purchased directly from China, from Chinese grocers in Los Angeles, and from the Internet. In conjunction with the University of Mississippi Natural Products Lab, which utilizes more sensitive assays than the initial FDA investigation, we analyzed numerous samples of traditional RYR and two control samples. The quantitative analyses of several samples of traditional RYR are consistent (see Table 1 , samples [1] [2] [3] [4] [5] . No statins were present and the samples tested positive for typical Monascus pigments. Sample 6 was a preparation of supplemental RYR with Monacolin K content advertised as 0.4%. This powdered sample contained statin metabolites and was red, but contained none of the red pigment typically produced during traditional RYR fermentation. Furthermore, according to the prior literature, in properly prepared RYR, the ratio of Monacolin K to Monacolin K acid varies between 2:1 and 1.5:1. 11 The ratio noted in analysis of sample 6 is 3:1, which suggests spiking of the sample with purified lovastatin. Sample 7 was Red Glutinous Rice, which is not a fermented product and did not contain statins or pigment. With this result, we essentially confirmed an important and not well-known conclusion from the FDA investigation. Additionally, our argument in our Letter to the Editor was proven false simply because of the absence of statin content in the traditional RYR samples.
The absence of statin content in the traditional RYR food products provides an additional solid argument against the usage of RYR supplements by our patients who insist on using a ''natural product.'' RYR supplement is a product produced by industrial methods under carefully controlled conditions. There exists a marked variability in the statin content in commercial RYR supplements. 12 The literature has additionally documented that some producers may spike their product with pharmaceutical lovastatin. 13 Therefore, at a minimum, our patients who insist on taking RYR supplements should be advised to consult the consumerlabs.com website. This website provides valuable information on various RYR products and statin content confirmed by independent laboratories.
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